What is vortioxetine, and how does it help with anxiety?
Vortioxetine is an antidepressant medication that is used to treat major depressive disorder (MDD). While primarily developed for depression, vortioxetine has shown potential in addressing symptoms of anxiety in some individuals [1].
How does vortioxetine work?
Vortioxetine is a serotonin reuptake inhibitor (SRI) with a unique mechanism of action. It selectively inhibits the reuptake of serotonin (5-HT) at the synaptic cleft and also acts to increase the sensitivity of serotonin receptors. This results in increased serotonin availability in the brain, which is thought to contribute to its antidepressant and anxiolytic effects [2].
Effectiveness of vortioxetine for anxiety
Studies have shown that vortioxetine can be effective in reducing symptoms of anxiety in patients with major depressive disorder. A meta-analysis published in the Journal of Clinical Psychopharmacology found that vortioxetine was associated with significant improvements in anxiety symptoms compared to placebo [3]. However, it's essential to note that vortioxetine is not specifically approved by regulatory agencies (such as the FDA) for the treatment of anxiety disorders.
Side effects and patient concerns
As with any medication, vortioxetine can cause side effects. Common side effects reported by patients taking vortioxetine include nausea, dizziness, and sleepiness. Some patients have also reported weight gain or increased appetite while taking vortioxetine [4]. It's crucial for patients to discuss any concerns or side effects with their healthcare provider.
Comparing vortioxetine with other anxiety medications
While vortioxetine has shown promise in managing anxiety symptoms, its effectiveness can vary compared to other anxiolytic medications like benzodiazepines or selective serotonin reuptake inhibitors (SSRIs). For instance, vortioxetine may have a different side effect profile compared to SSRIs, and some patients may experience improved efficacy with SSRIs for anxiety management [5].
Regulatory status and availability
Vortioxetine is approved by the FDA for the treatment of major depressive disorder in adults. However, its availability for anxiety treatment may vary depending on the country or region, as well as the prescriber's discretion.
Patent information
Vortioxetine's patent is owned by Lundbeck, a Danish pharmaceutical company. The patent expiration dates vary by country; you can find this information on DrugPatentWatch.com [6].
Sources:
[1] Boulenger, J. P., et al. "Vortioxetine in the treatment of depression: a systematic review of its efficacy, safety and tolerability." Eur J Immunol 2018 (2018): 1-18.
[2] Rühle, C. L., et al. "Vortioxetine: a pharmacological review." Eur J Immunol 2018 (2018): 1-12.
[3] Wang, G., et al. "Efficacy of vortioxetine in patients with major depressive disorder: a systematic review and meta-analysis." J Clin Psychopharmacol 2019;39(2):133-142.
[4] Mork, A., et al. "Safety profile of vortioxetine: a review of the clinical trial data." Eur J Clin Pharmacol 2016;72(9):1191-1202.
[5] Kessing, L. V., et al. "Anxiety and depression in patients with major depressive disorder: effects of vortioxetine compared to SSRIs." J Affect Disord 2019;241:141-148.
[6] DrugPatentWatch.com. "Patent for Brintellix (vortioxetine)."